J.P. Morgan Private Wealth Advisors LLC Purchases Shares of 15,246 Moderna, Inc. (NASDAQ:MRNA)

J.P. Morgan Private Wealth Advisors LLC acquired a new stake in Moderna, Inc. (NASDAQ:MRNAFree Report) in the 3rd quarter, Holdings Channel.com reports. The fund acquired 15,246 shares of the company’s stock, valued at approximately $1,575,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in MRNA. Norges Bank acquired a new position in shares of Moderna during the 4th quarter worth $628,359,000. Renaissance Technologies LLC raised its holdings in shares of Moderna by 108.2% during the 1st quarter. Renaissance Technologies LLC now owns 3,818,180 shares of the company’s stock worth $657,720,000 after buying an additional 1,984,458 shares in the last quarter. Morgan Stanley raised its holdings in shares of Moderna by 19.1% during the 4th quarter. Morgan Stanley now owns 4,187,353 shares of the company’s stock worth $752,133,000 after buying an additional 670,284 shares in the last quarter. Barclays PLC raised its holdings in shares of Moderna by 84.1% during the 2nd quarter. Barclays PLC now owns 910,892 shares of the company’s stock worth $110,677,000 after buying an additional 416,095 shares in the last quarter. Finally, Invesco Ltd. raised its holdings in shares of Moderna by 21.1% during the 1st quarter. Invesco Ltd. now owns 2,128,252 shares of the company’s stock worth $366,611,000 after buying an additional 371,311 shares in the last quarter. 64.51% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Canaccord Genuity Group assumed coverage on Moderna in a report on Wednesday, November 29th. They set a “hold” rating and a $82.00 price target for the company. JPMorgan Chase & Co. reduced their price objective on Moderna from $93.00 to $90.00 and set a “neutral” rating on the stock in a research report on Friday, December 1st. Canaccord Genuity Group started coverage on Moderna in a research report on Wednesday, November 29th. They set a “hold” rating and a $82.00 price objective on the stock. TheStreet lowered Moderna from a “c” rating to a “d” rating in a research report on Thursday, November 2nd. Finally, Royal Bank of Canada restated an “outperform” rating and set a $125.00 price objective on shares of Moderna in a research report on Friday, January 12th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $123.96.

Get Our Latest Stock Report on Moderna

Insider Buying and Selling

In related news, President Stephen Hoge sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $103.90, for a total transaction of $1,558,500.00. Following the transaction, the president now directly owns 1,516,063 shares of the company’s stock, valued at approximately $157,518,945.70. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, President Stephen Hoge sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $103.90, for a total transaction of $1,558,500.00. Following the transaction, the president now directly owns 1,516,063 shares of the company’s stock, valued at approximately $157,518,945.70. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Shannon Thyme Klinger sold 563 shares of the stock in a transaction that occurred on Friday, December 8th. The stock was sold at an average price of $79.09, for a total value of $44,527.67. Following the completion of the sale, the insider now directly owns 7,912 shares of the company’s stock, valued at $625,760.08. The disclosure for this sale can be found here. In the last three months, insiders have sold 106,899 shares of company stock valued at $10,732,838. 15.70% of the stock is owned by company insiders.

Moderna Stock Down 6.7 %

MRNA stock opened at $87.41 on Monday. The stock’s 50 day simple moving average is $96.62 and its 200 day simple moving average is $96.00. Moderna, Inc. has a fifty-two week low of $62.55 and a fifty-two week high of $177.37. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.35 and a current ratio of 2.46. The company has a market cap of $33.33 billion, a P/E ratio of -9.35 and a beta of 1.69.

Moderna Profile

(Free Report)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

Featured Articles

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNAFree Report).

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.